Business

AbbVie: Next-Generation Skyrizi and Rinvoq Are Showing Traction in Humira Space

February 21st 2020

By Skylar Jeremias

Pharmaceutical giant AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira (adalimumab) sales decline and more biosimilars to the blockbuster arthritis drug enter the market.

Remove Roadblocks to Streamline the Biosimilar Approval Process, Industry Veteran Says

February 14th 2020

By Tony Hagen

Article

Sarfaraz K. Niazi, PhD, a pharma industry veteran and consultant for biosimilar makers, discusses ins and outs of the approvals process that cause frustration and unnecessary expense.

Understanding the Risks, Opportunities, and Prospects of Biosimilars in 2020 and Beyond

February 14th 2020

By Steven Lucio, PharmD, BCPS

Article

Hurdles to a vibrant biosimilar market are not as insurmountable as they appear.

As Patents Expire, Oncology Biosimilars Poised to Expand, Authors Say

February 12th 2020

By Deana Ferreri, PhD

Article

By 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs, according to a review article.

Pipeline Report: Oncology Biosimilars to Advance in 2020

February 10th 2020

By Tony Hagen

Article

Biosimilars are starting to gain some traction in the marketplace, according to a speaker reviewing the 2020 pipeline at the Specialty Therapies and Biosimilars Congress.

Merck to Spin Off Biosimilars Business to Focus on Pembrolizumab

February 5th 2020

By Allison Inserro

Article

Merck markets a biosimilar infliximab, Renflexis; a biosimilar trastuzumab, Ontruzant; and a biosimilar etanercept, Brenzys, in partnership with Samsung Bioepis.

Reference-Based Drug Pricing Shifts Mix of Therapies, Lowers Prices Paid, Study Finds

February 5th 2020

By Allison Inserro

Article

Reference pricing may shift the mix of drugs dispensed from those offering the highest rebates to pharmacy benefit managers to those offering the lowest prices to employers and employees, according to a new study published Wednesday.

FDA, FTC Pledge Close Cooperation to Create Biosimilar Competition

February 4th 2020

By Allison Inserro

Article

The FDA and the Federal Trade Commission (FTC) will work more closely to support a more competitive market for biosimilars and interchangeable products. In addition, the FDA published draft guidance for industry about how to advertise and promote biologic products truthfully and announced a public workshop.

How Can Value-Based Care Embrace the Possibilities of Biosimilars?

February 3rd 2020

By Sara Karlovitch

Article

In case you missed it: Jeffery Scott, MD, chief medical officer of Integra Connect, discussed what role biosimilars will play in a value-based system on a recent podcast episode of Not So Different.

Celltrion's Wuhan Plans on Hold Amid Coronavirus Outbreak

February 3rd 2020

By Tony Hagen

Article

The company has recalled its employees from Wuhan until the outbreak is brought under control, as have many other outside companies and government agencies with workers in the Chinese market affected by the coronavirus.